Effects of a novel GABA‐B positive allosteric modulator, ASP8062, on alcohol cue‐elicited craving and naturalistic alcohol consumption in a multisite randomized, double‐blind, placebo‐controlled trial
Joseph P. Schacht,Lara A. Ray,Robert Miranda Jr.,Daniel E. Falk,Megan L. Ryan,Joseph T. Sakai,Karen Miotto,Thomas Chun,Charles Scott,Janet Ransom,Nour Alsharif,Mototsugu Ito,Raye Z. Litten
DOI: https://doi.org/10.1111/acer.15468
2024-12-04
Alcoholism Clinical and Experimental Research
Abstract:Among individuals with alcohol use disorder (AUD), the GABAB positive allosteric modulator ASP8062 has been hypothesized to exert similar effects as the GABAB agonist baclofen without the adverse effect profile associated with full agonism of this receptor. However, in this randomized, placebo‐controlled trial, ASP8062, relative to placebo, did not reduce alcohol cue‐elicited craving, nor did it affect alcohol consumption or other secondary outcomes, suggesting that positive allosteric modulation of the GABAB receptor may not be an efficacious treatment for AUD. Background The γ‐aminobutyric acid‐B (GABAB) receptor is a promising target for the development of new medications to treat alcohol use disorder (AUD). The GABAB agonist baclofen has been reported to reduce alcohol consumption but is associated with some undesirable side effects, including sedation. ASP8062 is a novel compound that acts as a positive allosteric modulator at the GABAB receptor and may be more tolerable than baclofen. This proof‐of‐concept human laboratory clinical trial evaluated the safety profile of ASP8062 and tested its effects on cue‐elicited alcohol craving and alcohol use among treatment‐seeking individuals with AUD. Methods This double‐blind, randomized, multisite trial tested the effect of ASP8062 (25 mg once daily), relative to placebo, on alcohol cue‐elicited craving in a laboratory setting and alcohol consumption, craving, mood, sleep, cigarette smoking, and alcohol‐related consequences in the natural environment over a 6‐week treatment period. Participants were 60 individuals (26 females and 34 males) with moderate or severe AUD. Results ASP8062, relative to placebo, was well tolerated, and there were no adverse events (AEs) that significantly differed between treatment groups. Most AEs were mild/moderate, and there were no serious AEs among individuals treated with ASP8062. However, ASP8062 did not attenuate alcohol cue‐elicited craving compared with placebo. Moreover, exploratory analyses indicated that ASP8062, relative to placebo, did not significantly affect alcohol consumption, naturalistic alcohol craving, mood, sleep, cigarette smoking, or alcohol‐related negative consequences during the 6‐week treatment period. Conclusions Although ASP8062 was well tolerated with no serious AEs, the novel compound did not significantly dampen alcohol cue‐elicited craving or improve other AUD‐related outcome measures. These data indicate positive allosteric modulation of the GABAB receptor at the dose evaluated here may not blunt alcohol cue‐elicited craving, and preliminary drinking outcome data suggest it may not be an efficacious treatment strategy for AUD.
substance abuse